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Abstract
Metabolic defects and neuronal apoptosis initiated by traumatic brain injury (TBI) contribute to subsequent
neurodegeneration. They are all regulated by mechanisms centered around mitochondrion. Type-1 cannabinoid
receptor (CB1) is a G-protein coupled receptor (GPCR) enriched on neuronal plasma membrane. Recent evidences
point to the substantial presence of CB1 receptors on neuronal mitochondrial outer membranes (mtCB1) and the
activation of mtCB1 influences aerobic respiration via inhibiting mitochondrial cyclic adenosine monophosphate
(cAMP)/protein kinase A (PKA)/complex I pathway. The expression and role of neuronal mtCB1 under TBI are
unknown. Using TBI models of cultured neurons, wild type and CB1 knockout mice, we found mtCB1 quickly
upregulated after TBI. Activation of mtCB1 promoted metabolic defects accompanied with ATP shortage but
protected neurons from apoptosis. Selective activation of plasma membrane CB1 showed no effects on neuronal
metabolism and apoptosis. Activation of mtCB1 receptors inhibited mitochondrial cAMP/PKA/complex I and
resulted in exacerbated metabolic defects accompanied with a higher ratio of ATP reduction to oxygen consumption
decrease as well as neuronal apoptosis. Further research found the remarkable accumulation of protein kinase B (AKT)
on neuronal mitochondria following TBI and the activation of mtCB1 upregulated mitochondrial AKT/complex
V activity. Upregulation of mitochondrial AKT/complex V activity showed anti-apoptosis effects and alleviated
ATP shortage in metabolic defects. Taken together, we have identified mtCB1 quickly upregulate after TBI and
a dual role the mtCB1 might play in metabolic defects and neuronal apoptosis initiated by TBI: the inhibition
of mitochondrial cAMP/PKA/complex I aggravates metabolic defects, energy insufficiency as well as neuronal
apoptosis, but the coactivation of mitochondrial AKT/complex V mitigates energy insufficiency and neuronal apoptosis.
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Introduction
Metabolic defects are common pathological processes
after traumatic brain injury (TBI) and relate to subse-
quent brain atrophy and cognitive dysfunction [1].
Metabolic defects following TBI are not the results of
ischemia or metabolic substrate insufficiency and the
underlying mechanisms are not definitely clarified. TBI
initiates a number of biochemical processes which lead to
massive ion shifts with increased calcium in the intracellu-
lar compartment. Calcium overload in mitochondrion
impairs mitochondrial function in aerobic metabolism
and eventually impedes energy production even when
there are sufficient oxygen and substrate present [2].
Neuronal apoptosis is another pervasive pathological
phenomenon responsible for the neurodegenerative
changes following TBI [3], which is also tightly associated
with the mitochondrial mechanisms [4].
Endocannabinoids are implicated in a broad range of
neurobiological processes including neuronal survival
after cerebral ischemia or trauma [5, 6]. Endogenous
cannabinoids produce the majority of their biological
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effects by activating two receptors: type-1 cannabinoid
receptor (CB1) and type-2 cannabinoid receptor (CB2).
CB1 receptors are the most abundant G-protein
coupled receptor (GPCR) in mammalian brain and ac-
count for most of the biological actions of cannabinoid
drugs. Neuronal CB1 receptors are the more abundant
CB1 receptors which are highly enriched on neuronal
plasma membranes. Although, the CB1 receptors are
identified as typical plasma membrane GPCRs, recent
evidences have pointed to the substantial presence of
CB1 receptors on neuronal mitochondrial outer mem-
branes and their activation influences mitochondrial
cyclic adenosine monophosphate (cAMP) accumula-
tion, protein kinase A (PKA) activity, complex I activity
and mitochondrial respiration [7].
The expression and roles of neuronal mtCB1 under
TBI are currently unknown. Considering the central role
of mitochondria in regulating cellular aerobic metabol-
ism and apoptosis, it is reasonable to hypothesize mtCBI
might play roles in TBI-induced metabolic defects and
neuronal apoptosis. Here, we investigated the early ex-
pression of neuronal mtCB1 and it’s action on metabolic
defects and neuronal apoptosis following TBI by select-
ively using cell-permeable or impermeable CB1 receptor
ligands in TBI models of cultured neurons, wild type
and CB1 knockout mice.
Results
TBI induced acute upregulation of mtCB1 receptors
At first, we investigated the expression of mtCB1 recep-
tors at acute stage on ipsilateral cortex and cultured
neuron post lesion. WB analysis revealed TBI caused
great upregulation of CB1 receptors on mitochondria
(2.5 times higher than sham in cortex of wild type mice
and 3.5 times higher than sham in cultured neurons)
24 h post injury (Fig. 1a and b). Only relatively small
CB1 increase was observed on plasma membranes
(1.16 times higher than sham in cortex of wild type mice
and 1.25 times higher than sham in cultured neurons)
24 h post injury (Fig. 1c, d). CB1 expression could hardly
be detected in CB1 knockout mice (Fig. 1a, c).
Activation of mtCB1 aggravated metabolic defects
following TBI
Next, we investigated the effects of CB1 on aerobic
metabolism after TBI in vivo. The cell-permeable CB1
agonist tetrahydrocannabinol (THC, 5 mg/kg) and an-
tagonist/inverse agonist AM251 (0.5 mg/kg) were used
to control the activity of intracellular CB1 receptors.
Microdialysis in wild type brains from 22 to 27 h
post injury showed lower glucose and pyruvate levels,
and increased lactate level as well as lactate/pyruvate
ratio (LPR) (Fig. 2A1–A4). Metabolic defects were
also demonstrated by the changed levels of metabo-
lites in injured CB−/− brains (Fig. 2B1–B4). It was
noticeable that CB1 knockout promoted metabolic defects
after TBI as demonstrated by microdialysis of metabolite
levels in CB−/− and wild type mice (p < 0.05).
In wild type mice, intraperitoneal administration of
THC (5 mg/kg) resulted in decreased glucose and
pyruvate levels, and increased lactate level as well as
LPR suggesting an aggravated metabolic condition
while AM251 showed opposite effects (Fig. 2A1–A4).
Metabolite analysis was also made in CB1−/− mice
treated with THC (5 mg/kg) or AM251 (0.5 mg/kg)
after injury and results showed metabolite levels were not
significantly differ from those of vehicle (Fig. 2B1–B4) in-
dicating the CB1 receptors were the specific targets of
THC and AM251. Single inhibition of plasma membrane
CB1 receptors by cell-impermeable CB1 antagonist/in-
verse agonist hemopressin (0.5 mg/kg) did not show
any effects on aerobic metabolism after TBI suggest-
ing the effects were due to the intracellular CB1 re-
ceptors (Fig. 2C1–C4).
To prove the effects were due to neuronal mtCB1 re-
ceptors but not CB1 receptors on other cells, we further
tested the metabolites in neuronal models treated with
cell-permeable CB1 ligands. In vivo after injury, as a re-
sult of the mitochondrial impairment, pyruvate no lon-
ger enters the tricarboxylic acid cycle and the need for
lactate decrease. On the other hand, pyruvate and glyco-
gen are heavily metabolized into lactate in astrocytes.
Therefore, lactate accumulates and pyruvate decreases in
Fig. 1 TBI induced acute upregulation of mtCB1 and plasma membrane CB1 24 h post injury. Western blot analysis of mtCB1 and plasma membrane
CB1 24 h post injury showed CB1 increased in mitochondria separated from cultured neurons and wild type mice after injury but not CB1−/− mice
(a, b). CB1 relatively slightly increased in plasma membrane fractions separated from cultured neurons and wild type mice after injury but not
CB1−/− mice (c, d). Cadherin is a plasma membrane protein, Tom20 is a mitochondrial protein. Values were expressed as mean ± SE (*p < 0.05
versus sham, ***p < 0.001 versus sham)
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the extracellular space, leading to the elevation of LPR
[8]. However, in neuronal model of injury without astro-
cytes, the neuronal need for pyruvate reduces and the
transformation of pyruvate into lactate greatly decreases
due to the lack of astrocytes. Therefore, pyruvate and
lactate both accumulate in the extracellular space [9].
Neuronal traumatic injury induced metabolic defects
demonstrated by higher extracellular pyruvate and lac-
tate levels, and reduced cellular oxygen consumption
and mitochondrial ATP concentration as compared to
sham group (Fig. 2D1–D4). In cultured neurons after in-
jury, the cell-permeable CB1 agonist HU210 (0.5 μM)
resulted in increased extracellular pyruvate (1.23 folds
higher than vehicle) and lactate (1.22 folds higher than
vehicle) levels, and reduced cellular oxygen consumption
(83.3 % of vehicle) and mitochondrial ATP concentra-
tion (95.3 % of vehicle) (Fig. 2D1–D4). The AM251
(5 μM) decreased extracellular pyruvate (82.6 % of
vehicle) and lactate (84.1 % of vehicle) levels, and in-
creased cellular oxygen consumption (1.36 folds higher
than vehicle) and mitochondrial ATP concentration
(1.06 folds higher than vehicle) (Fig. 2D1–D4). HU210
(0.5 μM) and AM251 (5 μM) were also administrated to
primary neuronal cultures prepared from CB1−/− mouse
(CB1−/− neurons). HU210 or AM251 did not change brain
metabolism in injured CB1−/− neurons (Fig. 2E1–E4).
Then we selectively controlled the plasma CB1 recep-
tors by hemopressin (5 μM) or cell-impermeable CB1
agonist HU210-biotin (0.5 μM) in cultured neurons. No
changes were found in extracellular metabolite levels,
oxygen consumption or mitochondrial ATP concentra-
tion after treatment (Fig. 2F1–F4).
To determine the effects were due to the direct modu-
lation of mtCB1 or to an indirect function of CB1 recep-
tors located on other intracellular organelles such as
lysosomes [10], mitochondria were purified from injured
neurons, wild type and CB1−/− mice after injury then
Fig. 2 MtCB1 regulated metabolic defects following TBI. Traumatic
injury changed metabolite levels in wild types, CB−/− mouse brains
as well as neuronal models (A1–A4, B1–B4 and D1–D4). THC and
AM251 reversely mediated metabolite levels in wild type mice brain
following TBI (A1–A4). THC and AM251 did not affect metabolite
levels in CB−/− mice brain following TBI (B1–B4). Hemopressin did not
affect metabolite levels in wild type mice brain following TBI (C1–C4).
Traumatic injury changed metabolite levels in cultured neuronal
models (D1–D4). HU210 and AM251 reversely mediated metabolite
levels in cultured neurons following injury (D1–D4). HU210 and AM251
did not changed metabolite levels in cultured CB−/− neurons following
injury (E1–E4). HU210-biotin and hemopressin did not affect metabolite
levels in cultured neurons (F1–F4). HU210 and AM251 reversely
mediated metabolite levels in mitochondria separated from cultured
neurons or wild-type mice after injury, but not in mitochondria from
CB1−/− mice after injury (G1-G4). Data were expressed as mean ± SE
(**p < 0.01 versus sham, ***p < 0.001 versus sham, #p < 0.05 versus
vehicle, ##p < 0.01 versus vehicle, ###p < 0.001 versus vehicle)
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treated with HU210 (0.5 μM) or AM251 (5 μM). The
drugs still apparently controlled pyruvate and lactate
levels, oxygen consumption and ATP concentration in
mitochondria separated from cultured neurons or wild-
type mice after injury, but not in mitochondria separated
from CB1−/− mice after injury (Fig. 2G1–G4).
MtCB1 activation protected neurons from apoptosis
following injury
In wild type model of TBI treated with vehicle, about
8.9 % cells in vivo and 20.1 % in vitro showed apoptosis
24 h post injury (Fig. 3a, b). TUNEL study 24 h post in-
jury showed THC (5 mg/kg in vivo and 10 μM in vitro)
or HU-210 (0.1 mg/kg in vivo and 0.5 μM in vitro) sig-
nificantly mitigated cellular apoptosis (4.1 % in vivo and
9.7 % in vitro in THC, 6.7 % in vivo and 13.7 % in vitro
in HU-210), while the AM251 (0.5 mg/kg in vivo and
5 μM in vitro) significantly promoted apoptosis (11.6 %
in vivo and 24.8 % in vitro) (Fig. 3a, b). In CB1−/−
models, the same dose of THC, HU-210 or AM251 did
not affect cellular apoptosis both in vivo and vitro com-
pared with the vehicle indicating the effects were due to
CB1 receptors (Fig. 3c, d). It was noticeable that CB1
knockout promoted neuronal apoptosis both in vivo
and vitro as demonstrated by the number of TUNEL
positive cells in CB1−/− and wild type treated with ve-
hicle (p < 0.05) (Fig. 3a, b, c and d). In vitro of wild
type hemopressin or HU210-biotin did not show any
effects suggesting the neuronal plasma membrane
CB1 receptors were not involved, however in vivo of wild
type hemopressin promoted apoptosis and HU210-biotin
inhibited apoptosis (Fig. 3e, f ).
The mitochondrion serve as a crucial role in regu-
lating neuronal apoptosis in TBI, both as an amplifier
of extrinsic pro-apoptotic signal and the source of the
activation of intrinsic apoptotic pathway [4]. The
mitochondrial apoptotic pathway is classified as cas-
pase dependent or caspase independent. In a caspase
dependent pathway, cyt c is the necessary participant,
whereas apoptosis inducing factor (AIF) is involved in the
caspase independent pathway. Under pro-apoptotic
stimulation such as traumatic injury, the release of cyt c
from mitochondria into the cytosol triggers apoptosome
assembly and the subsequent caspase activation and
apoptosis, while the AIF is released and translocated
into the nucleus to promote caspase independent
DNA degradation [11].
To determine the effects were due to the direct modu-
lation of mtCB1 or to an indirect function of CB1 recep-
tors located on other intracellular organelles which
could also be modulated by cell-permeable ligands,
mitochondria were purified from injured neurons, wild
type and CB1−/− mice 24 h after injury and treated with
HU210 (0.5 μM) or AM251 (5 μM). Cyt c and AIF
release were measured in supernatants following pellet-
ing of the mitochondrial suspensions. Immunoblots of
supernatants revealed HU-210 significantly inhibited cyt
c (36.5 % of vehicle in mitochondria of neurons and
73.2 % of vehicle in mitochondria of wild types) and AIF
(41.0 % of vehicle in mitochondria of neurons and
76.0 % of vehicle in mitochondria of wild types) release,
whereas AM251 promoted cyt c (2.84 folds higher than
vehicle in mitochondria of neurons and 1.79 folds higher
than vehicle in mitochondria of wild types) and AIF
(2.49 folds higher than vehicle in mitochondria of neu-
rons and 1.59 folds higher than vehicle in mitochondria
of wild types) release (Fig. 3g, h).
Mitochondrial cAMP/PKA/complex I inhibition promoted
metabolic defects and neuronal apoptosis
As mitochondrial cAMP/PKA/complex I pathway has
been found to be the downstream target of mtCB1 and
is involved in mtCB1 mediated aerobic metabolism of
normal neurons [7]. We tested the possible effects of
mitochondrial cAMP/PKA/complex I pathway on meta-
bolic defects and neuronal apoptosis after TBI. Mito-
chondria were purified from injured neurons and wild
type mice then treated with HU-210 (0.5 μM), AM251
(5 μM), H89 (a well-known pharmacological inhibitor of
PKA, 1.0 mM), rotenone (specific and potent mitochon-
drial complex I inhibitor, 2.5 μM) or forskolin (a select-
ive activator of adenylate cyclase, 1.5 mM). The results
showed HU-210 significantly decreased mitochondrial
cAMP concentration (59.7 % of vehicle in mitochondria
of neurons and 68.0 % of vehicle in mitochondria of
wild types), PKA activity (70.8 % of vehicle in mito-
chondria of neurons and 79.2 % of vehicle in mitochon-
dria of wild types) and complex I activity (77.8 % of
vehicle in mitochondria of neurons and 86.2 % of ve-
hicle in mitochondria of wild types), while AM251
showed opposite effects on them (1.47 folds higher than
vehicle in mitochondria of neurons and 1.38 folds
higher than vehicle in mitochondria of wild types to
cAMP, 1.37 folds higher than vehicle in mitochondria
of neurons and 1.29 folds higher than vehicle in mito-
chondria of wild types to PKA, 1.26 flods higher than
vehicle in mitochondria of neurons and 1.17 folds
higher than vehicle in mitochondria of wild types to
complex I) (Fig. 4A1, B1).
The inhibition of mitochondrial cAMP/PKA/complex
I activity by H89 significantly increased extramitochon-
drial pyruvate (1.15 folds higher than vehicle in mito-
chondria of neurons and 1.13 folds higher than vehicle
in mitochondria of wild types) and lactate levels (1.13
folds higher than vehicle in mitochondria of neurons
and 1.11 folds higher than vehicle in mitochondria of
wild types), and decreased oxygen consumption (88.5 %
of vehicle in mitochondria of neurons and 90.5 % of
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vehicle in mitochondria of wild types) accompanied with
ATP insufficiency (90.8 % of vehicle in mitochondria of
neurons and 93.0 % of vehicle in mitochondria of wild
types) (Fig. 4A3, B3). The ratio of ATP decrease to oxy-
gen consumption reduction (percentage of ATP reduc-
tion/percentage of oxygen consumption reduction =
12.7 %/13.8 % in mitochondria of cultured neurons,
7.0 %/9.5 % in mitochondria of wild type mice) is higher
than that of mtCB1 activation (percentage of ATP reduc-
tion/percentage of oxygen consumption reduction =
4.7 %/16.7 % in cultured neurons, 7.2 %/27.2 % in
mitochondria of cultured neurons, 5.3 %/16.2 % in mito-
chondria of wild type mice) (p < 0.05). Parallel supernatant
cyt c and AIF analysis demonstrated a significant promo-
tion of mitochondrial cyt c (1.71 folds higher than vehicle
in mitochondria of neurons and 1.68 folds higher than ve-
hicle in mitochondria of wild types) and AIF (1.64 folds
higher than vehicle in mitochondria of neurons and 1.61
folds higher than vehicle in mitochondria of wild types)
release was induced by H89 (1.0 mM) treatment (Fig. 4A2,
A3, B2 and B3). Similar results (1.19 folds higher than ve-
hicle to pyruvate, 1.17 folds higher than vehicle to lactate,
Fig. 4 MtCB1 regulated neuronal metabolic defects and apoptosis through mitochondrial cAMP/PKA/complex I pathway. HU-210 inhibited
cAMP/PKA/complex I activity in mitochondria purified from injured neurons and wild type mice while AM251 showed opposite effect (A1, B1).
Mitochondrial cAMP/PKA/complex I pathway inhibitor H89 or rotenone promoted mitochondrial metabolic defects, cyt c and AIF release (A2, A3,
B2 and B3) while the activator forskolin showed opposite effects (A4 and B4). HU210 and AM251 did not affect cAMP/PKA/complex I activity in
mitochondria purified from CB−/− mice following injury (c). Tom20 is a mitochondrial protein. Data were expressed as mean ± SE. (#p < 0.05
versus vehicle, ##p < 0.01 versus vehicle)
(See figure on previous page.)
Fig. 3 MtCB1 regulated neuronal apoptosis following injury. Both in vivo and vitro of wild type 24 h post injury, TUNEL study showed THC and
HU210 protected neurons from apoptosis while AM251 promoted apoptosis compared with vehicle (a, b). THC, HU-210 or AM251 did not affect
cellular apoptosis both in vivo and vitro of CB1−/− (c, d). Compared with vehicle, hemopressin or HU210-biotin did not affect cellular apoptosis in
vitro of wild type but reversely mediated apoptosis in vivo of wild type (e, f). Western blot analysis showed HU210 or AM251 reversely mediated
mitochondrial cyt c and AIF release of wild type both in vivo and vitro but not in CB1−/− mice (g, h). Nuclear morphology was indicated
by DAPI staining and DNA breaks were detected by TUNEL analyses. Tom20 is a mitochondrial protein. bar: 25 μm. Data were expressed
as mean ± SE (#p < 0.05 versus vehicle, ##p < 0.01 versus vehicle, ###p < 0.001 versus vehicle)
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86.2 % of vehicle to oxygen consumption, 87.3 % of ve-
hicle to ATP production, 1.60 folds higher than vehicle to
cyt c and 1.44 folds higher than vehicle to AIF in mito-
chondria of neurons/1.17 folds higher than vehicle to
pyruvate, 1.15 folds higher than vehicle to lactate, 88.2 %
of vehicle to oxygen consumption, 89.3 % of vehicle to
ATP production, 1.58 folds higher than vehicle to cyt c
and 1.40 folds higher than vehicle to AIF in mitochondria
of wild types) were also seen in rotenone treatment groups
(Fig. 4A2, A3, B2 and B3). The forskolin treatment
showed opposite effects in mitochondria separated from
cultured neurons and wild type mice (Fig. 4 A4, B4).
Same dose of HU-210 and AM251 were also adminis-
trated to mitochondria separated from CB1−/− mice.
Results showed no changes were found in mitochon-
drial cAMP/PKA/complex activity suggesting CB1 re-
ceptors were the specific targets (Fig. 4c).
Protein kinase B (AKT) accumulated in neuronal
mitochondria after TBI and mtCB1 activation upregulated
mitochondrial AKT/complex V activity
The direct downregulation of mitochondrial cAMP/PKA/
complex I resulted in a lower efficiency of ATP synthesis
compared with that of mtCB1 activation as demon-
strated by higher ratio of ATP decrease to oxygen
consumption reduction. In addition, direct mitochon-
drial PKA/complex I inhibition increased cyt c and
AIF release which incurred neuronal apoptosis. This
was opposite to the anti-apoptosis effects of direct
mtCB1 activation as demonstrated in our experiment.
Thus we deduced that there might have another anti-
apoptosis pathway involved in the mtCB1 activation.
Protein kinase B (AKT) which is another well-known
downstream target of CB1 was studied. At first, we
tested whether there was mitochondrial accumulation of
AKT under the stimulation of TBI. Western blots were
performed on mitochondria separated from cultured
neurons, wild type and CB−/− mice. Western blots ana-
lysis showed approximately 5.3–6.3 folds increase to
AKT protein expression in mitochondria separated from
cultured neurons (5.33 folds higher than sham), wild
type (6.26 folds higher than sham) and CB1−/− mice
(6.07 folds higher than sham) 24 h after injury (Fig. 5A1,
A2). Although the AKT value in mitochondria from wild
type TBI model was higher than that of CB1−/− mice,
the difference was statistically nonsignificant (p > 0.05)
Fig. 5 TBI induced AKT accumulation in neuronal mitochondria and mtCB1 regulated mitochondrial AKT/complex V activity. Western blot analysis
of mitochondrial total AKT and pAKT showed AKT greatly increased in mitochondria separated from neurons, wild type or CB1−/− mice 24 h post
injury and most of them are unphosphorylated (A1 and A2). HU210 increased AKT/complex V activity in mitochondria purified from cultured
neurons or wild type mice while AM251 showed opposite effects (A3 and A4). HU-210 and AM251 did not affect AKT/complex V activity in
mitochondria from CB1−/− mice (b). Tom20 is a mitochondrial protein. Data were expressed as mean ± SE. (##p < 0.01 versus vehicle, *p < 0.05
versus sham, ***p < 0.001 versus sham)
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indicating the CB1 knockout did not influence mito-
chondrial AKT accumulation following TBI. Then,
phospho-Ser473-AKT and phospho-Thr308-AKT, two
main kind of phosphorylated AKT, were analyzed and
results showed only a minor increase of phosphorylated
AKT (1.32, 1.29 and 1.32 folds higher than sham in
mitochondria of wild types, CB−/− and neurons respect-
ively to pSer473-AKT/1.20, 1.19 and 1.29 folds higher
than sham in mitochondria of wild types, CB−/− and
neurons respectively to pThr308-AKT) was found on
mitochondria suggesting the TBI-induced AKT accumu-
lation on mitochondria might largely be unphosphory-
lated (Fig. 5A1).
Then we tested the effects of mtCB1 activation on
mitochondrial AKT and complex V activity. The results
showed HU-210 (0.5 μM) significantly increased mito-
chondrial AKT (1.76 folds higher than vehicle in mito-
chondria of neurons and 1.71 folds higher than vehicle
in mitochondria of wild type) and complex V (1.63 folds
higher than vehicle in mitochondria of neurons and 1.59
higher than vehicle in mitochondria of wild types) activ-
ities, while AM251 (5 μM) showed opposite effects
(56.3 % of vehicle in mitochondria of neurons and
60.8 % of vehicle in mitochondria of wild type to AKT/
65.0 % of vehicle in mitochondria of neurons and 67.2 %
of vehicle in mitochondria of wild types to complex V)
on them (Fig. 5A3, A4). Same dose of HU-210 and AM251
did not show any effects on mitochondria from CB1−/−
mice indicating the effects were due to CB1 reporters
(Fig. 5b).
Mitochondrial AKT activation alleviated neuronal
metabolic defects and apoptosis
Then we investigated if the activation of mitochondrial
AKT/complex V was directly involved in the protection
effects on metabolic defects and apoptosis after TBI.
Mitochondria were purified from injured neurons or
wild type mice then treated with sodium valproate
(VPA, 1.0 mM) which could increase the activation
dependent phosphorylation of Ser-473 of AKT through
inhibitory effect on histone deacetylase [12].
The results showed VPA resulted in decreased pyru-
vate (89.5 % of vehicle in mitochondria of neurons
and 91.2 % of vehicle in mitochondria of wild types)
and lactate (90.3 % of vehicle in mitochondria of neu-
rons and 91.5 % of vehicle in mitochondria of wild
types), and increased oxygen consumption (1.10 folds
higher than vehicle in mitochondria of neurons and
1.09 folds higher than vehicle in mitochondria of wild
types) accompanied with raised ATP supply (1.33 folds
higher than vehicle in mitochondria of neurons and 1.21
folds higher than vehicle in mitochondria of wild types)
(Fig. 6A1, B1). The ratio of ATP rise to oxygen consump-
tion increase (percentage of ATP increase/percentage of
oxygen consumption increase = 133 %/110 % in mito-
chondria from neuron, 121 %/109 % in mitochondria from
Fig. 6 Mitochondrial AKT/complex V pathway regulated neuronal metabolic defects and apoptosis. AKT activator VPA alleviated metabolic
defects, cyt c and AIF release in mitochondria purified from injured neurons or wild type mice (A1 and B1). Preincubation 30 min with AKT
specific inhibitor API-2 counteracted the VPA induced cyt c and AIF release and a concentration-dependent effect was induced by 2.0 and
4.0 mM VPA (A2, A3, B2 and B3). Tom20 is a mitochondrial protein. Data were expressed as mean ± SE. (#p < 0.05 versus vehicle, ##p < 0.01
versus vehicle)
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wild type mice) was higher than that of mtCB1 activation.
Parallel supernatants cyt c and AIF analysis demonstrated
VPA significantly inhibited the mitochondrial cyt c
(31.2 % of vehicle in mitochondria of neurons and 34.0 %
of vehicle in mitochondria of wild types) and AIF (49.3 %
of vehicle in mitochondria of neurons and 45.2 % of ve-
hicle in mitochondria of wild types) release (Fig. 6A2, A3,
B2 and B3). Preincubation 30 min with AKT specific in-
hibitor API-2 (1 mM) significantly counteracted the VPA
(1 mM) induced cyt c (83.0 % of vehicle in mitochondria
of neurons and 64.8 % of vehicle in mitochondria of wild
types) and AIF release (66.8 % of vehicle in mitochondria
of neurons and 69.0 % of vehicle in mitochondria of wild
types) (Fig. 6A2, A3, B2 and B3). Examination of the
concentration dependent effects revealed that greater
responses were induced by 2.0 and 4.0 mM VPA
(Fig. 6A2, A3, B2 and B3).
Discussion
This is the first study to report on the effects of mtCB1
in TBI. Our results present clear evidence that at least
two pathways are the downstream targets of mtCB1 and
play a dual role in metabolic defects and neuronal apop-
tosis after TBI.
As the CB1 receptors traditionally are believed to exist
on the plasma membranes, neuroprotective effects of
the lipophilic cannabinoids are ascribed to nonspecific
alterations of membrane properties induced by plasma
membrane CB1 receptors. This study showed a relatively
small upregulation of plasma membrane CB1 receptors
compared to the strong upregulation of mitochondrial
CB1 receptors at the first 24 h after TBI. Considering
the fast and great increase of endogenous cannabinoid
levels (10-fold within 4 h) following TBI [5] there might
have a greater over activation of mtCB1 receptors at
least at the acute stage following TBI. Consequently we
further demonstrated mtCB1 activation promoted meta-
bolic defects accompanied with ATP shortage but
protected neurons from apoptosis. Although in vitro sin-
gle modulation of CB1 receptors located on neuronal
plasma membranes by cell-impermeable ligands did not
show significant effects, in vivo inhibition of plasma
membrane CB1 receptors by cell-impermeable antagon-
ist promoted apoptosis and cell-impermeable agonist
inhibited apoptosis. The underlying cause of this differ-
ence between cultured neurons and mice treated with
cell-impermeable ligands was not definitely clarified in
this experiment, however it was not entirely unexpected.
According to previous reports, except for neurons,
CB1 receptors also express on the cerebromicrovascu-
lar endothelial cells which represent the main compo-
nent of the blood brain barrier and are involved in
endocannabinoid (eCB) system mediated vasodilation,
astrocytes and microglias all of which are main
sources of inflammatory mediators following TBI [13–15].
In vivo studies have proved activation of plasma
membrane CB1 receptors displays neuroprotective ef-
fect based on the multipotent properties such as the
suppression of the formation of reactive oxygen spe-
cies (ROS), vasodilators, anti-inflammatory agents and
inhibitors of excitotoxicity [16].
The CB2 receptors which are well recognized on resi-
dent inflammatory cells within the CNS [17] and show
neuroprotective effects through attenuating inflamma-
tory response [18] might also be activated by the cell-
impermeable CB1 agonist, as most CB1 agonists show
little selectivity between the CB1 and CB2 receptors,
thus involved in the agonist-induced protective effects in
vivo. However, the contrary effects induced by the cell-
impermeable CB1 antagonist could demonstrate the
CB1 specificity as the CB1 antagonist compounds in-
cluding hemopressin and AM251 are highly selective
(>1000 fold selective for CB1 vs CB2) [19]. Thus the
anti-apoptosis effect by cell-impermeable CB1 agonist in
vivo might be due to the activation of plasma membrane
CB1 receptors located on non-neuronal cells in brain.
For further exploring the mechanisms underlying the
mtCB1 modulated aerobic metabolism and apoptosis,
mitochondrial cAMP/PKA/complex I pathway was ex-
amined in mitochondria after treating with CB1 ligands.
We did find mtCB1 activation inhibited mitochondrial
cAMP/PKA/complex I signaling pathway and direct
cAMP/PKA/complex I inhibition by CB1 agonist did ag-
gravate metabolic defects as mentioned by Bénard [7].
However, cAMP/PKA/complex I inhibition also pro-
moted mitochondrial cyt c and AIF release, implying a
pro-apoptosis effect. This phenomenon is also consistent
with the common sense that the insufficient energy sup-
ply aggravates mitochondrial impairment induced by
TBI due to the failure of energy dependent membrane
ion pumps to facilitate restoration of ionic gradients,
thus, promotes apoptosis. It was paradoxical that mtCB1
activation via mitochondrial cAMP/PKA/complex I
pathway inhibition aggravated metabolic defects accom-
panied with ATP insufficiency but protected neurons
from apoptosis following TBI. In addition, the ratio of
ATP decrease to oxygen consumption reduction after
direct cAMP/PKA/complex I inhibition by H89 or rote-
none was higher than that of indirect inhibition by CB1
agonist indicating mtCB1 activation might have miti-
gated ATP uncoupling in oxidative phosphorylation. De-
crease in the coupling of the electron transport chain
and oxidative phosphorylation followed by lower ATP
production has been demonstrated shortly after TBI in
rodents [20].
AKT (also known as PKB or RAC-PK) is an intracellu-
lar serine/threonine kinase involved in regulating cell
survival. Under some stimuli, including growth factors,
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hormones, and stressors, AKT translocates into mito-
chondria and the activation of mitochondrial AKT pro-
motes mitochondrial complex V activity which improves
ATP synthesis under the dysregulation of mitochondrial
oxidative phosphorylation and inhibits apoptosis in sev-
eral types of cells [21–23]. A significant body of works
show that activation of AKT promotes cell survival in
multiple in vitro and in vivo models where neuronal
death is seen, including TBI [24, 25]. The great accumu-
lation of AKT on mitochondria shortly after injury sug-
gested AKT activation might play a role in TBI. The
mechanisms for mitochondrial accumulation of AKT
have not been thoroughly investigated. Stimulation of a
variety of cell types with insulin-like growth factor-1
(IGF-1), insulin, or stress (induced by heat shock), in-
duces translocation of AKT to the mitochondria within
only several minutes of stimulation, causing increases of
nearly 8 to 12 folds, and the mitochondrial AKT is
found to reside in the matrix and the inner and outer
membranes [23]. Although not in the nervous system,
AKT overexpression by a mitochondria targeted consti-
tutively active AKT via adenoviral vector inhibits efflux
of cyt c and AIF from mitochondria to cytosol and par-
tially prevents loss of mitochondria cross membrane
electrochemical gradient, showing anti-apoptosis effect
[22]. As a large body of studies have revealed the early
and sustained increase in the expression of IGF-1 and
heat shock protein in brain following traumatic injury
[26, 27], a similar mechanism involved in IGF-1 or heat
shock protein induced mitochondrial AKT accumulation
might also be triggered by TBI. The cytoplasmic AKT is
activated when phosphorylated by G-protein βγ subunits
of plasma membrane CB1 receptor [28]. The presence of
AKT in the intermembrane space, inner membrane,
outer membrane and matrix implies that it can connect
the mitochondrial CB1 and be phosphorylated.
The F1 portion of complex V anchors on the inner
membrane and protrudes into the matrix [29] and the β-
subunit of F1 portion which is the catalytic site for ATP
synthesis is one of the mitochondrial AKT’s substrates
[23]. Mitochondrial activation of AKT increases complex
V activity by 24 % in normal myocardium in vivo [21].
Through increasing complex V activity, the TBI triggered
accumulation and mtCB1 induced activation of AKT in
neuronal mitochondria might improve the coupling of
the electron transport chain and oxidative phosphoryl-
ation as indicated by the higher ratio of ATP rise to oxy-
gen consumption increase in this study.
The upregulated complex V activity might play an
indirect anti-apoptosis role because of the subsequently
increased energy supply. However the net supply of ATP
was still decreased following mtCB1 activation and the
anti-apoptosis effect of mtCB1 activation might not to-
tally depend on the improved energy supply. A number
of downstream targets of cytoplasmic AKT, such as
CREB, FoxO transcription factors and GSK3β, have also
been found on mitochondria [23, 30–32] and some of
them have been proved to modulate apoptosis through a
mitochondrial way [30]. A deeper investigation should
be necessary for determining the downstream mecha-
nisms of the mtCB1/AKT modulated neuronal apoptosis
following TBI.
Totally, these data suggest a dual role the activation of
mtCB1 receptors might play in TBI. The cAMP/PKA/
complex I inhibition aggravates metabolic defects, en-
ergy insufficiency as well as neuronal apoptosis but the
coactivation of AKT/complex V mitigates energy insuffi-
ciency and neuronal apoptosis. The discovery that mito-
chondrial CB1 signaling is involved in metabolic defects
and neuronal apoptosis following TBI further extends
the range of mechanisms through which endocannabi-
noid signaling protect brain from TBI and would
possibly add new pharmacological targets for the thera-
peutic exploitation in endocannabinoid system.
Methods
Animals and TBI procedure
Experimental animal was C57BL/6 J mouse, wild-type
(CB1+/+) afforded by animal experimental center of
Zhejiang Chinese Medicine University and homozy-
gous CB1 knockout mice (CB1−/−) [33]. The use and
care of animals employed in our models were ap-
proved by the Animal Care and Use Committee of
Zhejiang Chinese Medicine University, in accordance
with all relevant laws of china. Adult male CB1−/−
and CB1+/+ littermates (10–16 weeks) were housed
individually with an inverse 12/12 h light/dark cycle
for at least 2 weeks before experiment. Mice (n = 5 per
group) were suffered to TBI using a controlled cortical im-
pact (CCI) device (VCU Biomedical Engineering Facility,
Richmond, Virginia, USA) after anesthetized with isoflur-
ane evaporated in a gas mixture containing 70 % N2O and
30 % O2. Briefly, a craniotomy of 5-mm diameter was per-
formed over the right parietal cortex which centered
around 2.0 mm posterior to bregma and 2.0 mm lateral to
the midline. Injury was performed using a 3.0 mm
rounded metal tip that was aimed vertically to the brain
surface. The metal tip hit the brain at a speed of 4.5 m/s
resulting a deformation depth of 2.0 mm. Sham injured
mice underwent identical anesthesia and craniotomy pro-
cedure without CCI injury. Mice were placed for 2 h in an
incubator heated to 33 °C and at a humidity of 35 % to re-
cover in their individual cages.
Cell culture and injury procedure
Primary hippocampal neuron cultures were prepared
from 14-day wild type CB1+/+ and CB1−/− C57BL/6 J
mouse embryos as previously described and injured
Xu et al. Molecular Brain  (2016) 9:75 Page 10 of 14
using an established in vitro model for TBI as de-
scribed [34, 35]. The purity of cultured neurons was
proved by immunofluorescence with antibody targeted
to GFAP or IBA-1. Cells were suffered to severe in-
jury and the control wells were contained in the same
FlexPlates as injured wells, and thus underwent the
same manipulations, except not received the deform-
ation of the silastic membrane.
Synthesis of HU210-biotin and drug administration
The cell-impermeable biotinylated version of the lipo-
philic CB1 receptor agonist HU210 (HU210-biotin)
displaying a comparable affinity for CB1 receptors to
that of HU210 was used as plasma membrane CB1
receptor activator and was synthesized as previous de-
scribed [7]. Purity (elemental analysis) >95 %. Blood
brain barrier permeability of HU-210 in mouse (intra-
peritoneally, 0.1 mg per kilogram) was proved by
Nguyen VH [36]. Cell-impermeable antagonist hemo-
pressin, cell-permeable lipophilic antagonist AM251
and agonist THC were used in this experiment [7].
Intraperitoneal use of THC (5 mg per kilogram),
hemopressin (0.5 mg per kilogram) and AM251
(0.5 mg per kilogram) to rodent were based on previ-
ous studies [7, 37]. Injections were made in a volume
of 2 ml/kg body weight and the first dose adminis-
trated 30 min after injury and repeated 12 h after in-
jury. Drugs were added directly into cultured neurons
to reach the concentrations (5 μM hemopressin,
0.5 μM of HU210, 0.5 μM HU-biot, 10 μM THC and
5 μM AM251) 30 min after injury and repeated 12 h
later to keep the same concentrations without appar-
ent cellular toxicity. In purified mitochondria, Drugs
were added right after extraction and 30 min before
testing with the concentration same to neuron. H89
(1 mM), rotenone (2.5 μM), forskolin (1.5 mM), val-
proic acid (VPA, 1.0 mM, 2.0 mM and 4.0 mM) and
API-2 (1.0 mM) were also directly added into purified
mitochondria. Pharmaceutical chemicals were pur-
chased from Sigma-Aldrich.
Cell fraction isolation
Cortex from the ipsilateral injury site was rapidly excised
and cut into small pieces. Tissues or cells were homoge-
nized in isolation buffer (1 mM EDTA and DNAase and
protease inhibitor cocktail, PH7.4). The homogenate was
centrifuged at 1 000 g for 5 min. The supernatant was
strained through gauze and recentrifuged at 7 000 g for
10 min. The resulting pellets were resuspended in ice
cold isolation buffer for a new series of centrifugation
(1 000 and 7 000 g) for mitochondrial purification.
Then the supernatant was collected for centrifugation
for membrane fraction collection. A discontinues su-
crose gradient (1.0–2.5 M) was used to layer the
plasma membrane fractions. The crude mitochondrial
pellets were resuspended in ficoll medium and centri-
fuged for further purification. Protein concentration
was determined by the BCA assay. The mitochondria
were made up to a concentration of 50 mg protein/
ml in the buffer. The lysosome, cytosol and endoplas-
mic reticulum (ER) contaminations in purified mito-
chondria were investigated using antibodies against
LAMP1, GAPDH and calreticulin respectively. Few
lysosome, cytosol and ER contaminations were seen
in the purified mitochondria (data were not shown).
Western blots
All samples were supplemented with proteases inhibitor
(Roche) then diluted in sample buffer. Samples were
supplemented with 2 % beta-mercaptoethanol and
50 mM DTT and boiled for about 6 min. Proteins were
separated on tris-glycine 4–15 % acrylamide gels and
transferred to PVDF membranes. Membranes were
soaked in 5 % milk in PBS-Tween 20 (0.05–0.15 %).
Mitochondrial and plasma membrane proteins were de-
tected using rabbit anti-Tom-20 polyclonal antibody
(Santa Cruz, 1:200) and rabbit anti-cadherin polyclonal
antibody (Santa Cruz, 1:200). Lysosome, cytosol and
endoplasmic reticulum(ER) contaminations were investi-
gated using goat anti-LAMP1 polyclonal antibody (Santa
Cruz, 1:200), goat anti-GAPDH polyclonal antibody
(Santa Cruz, 1:200) and rabbit anti-calreticulin poly-
clonal antibody (Invitrogen, 1:300) respectively. The
presence of the CB1 receptors in mitochondria and
plasma membrane fractions was analyzed using rabbit
anti-CB1 polyclonal antibody directed against the C
terminus of the receptor (Cayman, 1:300). The mito-
chondrial total AKT, pS473-AKT and pT308-AKT were
tested with rabbit anti-AKT polyclonal antibody (Santa
Cruz, 1:300), rabbit anti-pS473-AKT polyclonal antibody
(Santa Cruz, 1:300), rabbit anti-pT308-AKT polyclonal
antibody (Santa Cruz, 1:300) respectively. AIF and cyt c
were analyzed with rabbit anti-AIF polyclonal antibody
(Santa Cruz, 1:500) and goat anti-cyt c polyclonal anti-
body (Santa Cruz, 1:1000). GFAP and IBA-1 were de-
tected with rabbit anti-GFAP polyclonal antibody (Santa
Cruz, 1:500) and rabbit anti- IBA-1 polyclonal antibody
(Santa Cruz, 1:500). Immunoreactivity was detected by
incubation with secondary HRP-coupled antibody for
1 h at room temperature followed by the ECL plus re-
agent (Santa Cruz). The optical densities of the bands
were calculated using a MiVnt image analysis system
(Bio-Rad, Carlsbad, CA, USA).
Microdialysis
Microdialysis study was initiated at 22 h post injury and
maintained for 6 h. A microdialysis catheter (CMA 12,
CMA Microdialysis, Sweden) was introduced through a
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guide cannula secured in a dedicated and distinct
burr hole placed 2 mm anteriorly to the craniectomy.
Perfusion was then initiated at 1 μL/min with CNS
perfusion fluid (CMA Microdialysis, Sweden) and
microdialysis samples collected every hour. Concen-
trations of glucose, pyruvate and lactate were mea-
sured using high performance liquid chromatography
(CMA 600, CMA Microdialysis, Sweden) and aver-
aged hourly for statistical analysis.
Measurement of extracellular lactate and pyruvate
concentrations
Twenty-four hours after injury, the growth medium in
six-well FlexPlates were collected, cells removed by cen-
trifugation at 1200 g for 5 min, then the lactate and
pyruvate concentrations were determined enzymatically
using Biovision assay kits according to instructions.
Oxygen consumption assay
Oxygen consumption was monitored at 30 °C in a
thermostatically controlled glass chamber equipped with
a clark oxygen electrode (Hansatech Instruments,
Norfolk, England). Mitochondria purified from aliquots of
cells were suspended in 1 mL of the respiration buffer
(75 mM mannitol, 25 mM sucrose, 10 mM KCl, 10 mM
Tris–HCl, 450 mM EDTA) in the chamber. Intact cells
were transferred directly in the chamber. Respiratory sub-
strates (10 mM pyruvate and 5 mM malate) were added
directly to the chamber. A coupled respiratory state was
obtained by adding 2 mM ADP.
Assay for ATP
ATP assay kits (Promega) were used 24 h after injury.
Aliquots of isolated mitochondria were digested with
2.5 % TCA and then neutralized with tris-acetate.
The luminescence was measured using synergy HT
multi-detection microplate reader. A 2 s delay time
after 100 μL rLuciferase/Luciferin reagent injection
and a 10s RLU signal integration time were used ac-
cording to the manual.
TUNEL staining
Consecutive coronal sections were cut from posterior
bregma-1 mm to bregma-2.5 mm with 150 μm intervals.
The thickness of every section was 8 μm and a total
number of 10 sections in each brain were collected for
terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end labeling (TUNEL) staining. TUNEL
staining was performed using an In Situ Cell Death De-
tection Kit (Roche Diagnostics, Mannheim, Germany) to
detect in situ DNA fragmentation. DAPI staining was
performed according to routine laboratory methods. The
images were viewed on an EVOS-fl digital inverted
fluorescent microscopy.
In each section, six non-overlapped vision fields were
randomly selected from regions surrounding the primary
contused site. The apoptotic index of each section was
calculated by the mean number of TUNEL/DAPI double
positive nuclei in the six views and the apoptotic index
for each animal was determined by the final average per-
centage of double positive cells of the 10 sections.
Cell apoptosis was assessed in cultured neurons ac-
cording to previous study [38]. Neurons in six contigu-
ous images were counted and averaged per well. All
these images were taken from the center portion of the
well, as this region was previously shown to receive
equal impact from the cell injury controller [35]. All cell
counting was performed blind.
Detection of cyt c and AIF release
Isolated neuronal mitochondria were incubated at 30 °C
for 50–80 min in 100 μL of KCl medium(125 mM KCl,
2 mM K2HPO4, 20 mM HEPES) supplemented with
5 mM succinate and 4 mM MgCl2. Mitochondrial sus-
pensions were centrifuged at 13 000 g for 6 min at 4 °C
at the end of the incubation period. Supernatants were
stored with Halt Protease Inhibitor Mixture® (Pierce)
at −80 °C. Pellets were also stored at −80 °C then re-
suspended in 100 μL of KCl medium containing 1 %
triton X-100 and Halt Protease Inhibitor Mixture®
prior to gel loading. Proteins retained in the mito-
chondrial pellets or released into the supernatants
were separated by SDS-PAGE. AIF and cyt c were
then detected by immunoblot.
Cyclic AMP, PKA and AKT activity assay
Cyclic AMP level, PKA and AKT activity were assayed
on isolated mitochondria using the Direct Correlate-EIA
cAMP kit (Assay Designs Inc) and an ELISA kit (Enzo
Life Science) respectively.
NADH-ubiquinone oxidoreductase (complex I) activity
assay
We followed the reaction of NADH oxidation into NAD+
by complex I on isolated mitochondria as previously
described [39].
Oxidative phosphorylation Complex V activity assay
Equal amount of mitochondrial protein was added to
800 μL pre-warmed distilled water and 200 μL pre-
warmed reaction buffer containing 50 mM Tris–HCl,
1 mM NADH, 5 mg/mL BSA, 20 mM MgCl2, 50 mM
KCl, 15 μM carbonyl cyanide m-chlorophenyl hydra-
zone, 10 mM phosphoenol pyruvate, 5 μM antimycin
and 4U of lactate dehydrogenase/pyruvate kinase at 37 °C.
The activity was measured by the absorbance at 340 nm
for 3 min. Twelve μM oligomycin was added to the reac-
tion mixture to determine the oligomycin-sensitive
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complex V activity. The abundance of complex V subunits
was analyzed with complex V immunocapture Kit
(Mitosciences).
Statistical analyses
All graphs and statistical analyses were performed using
IBM SPSS software (version 21.0). Results are expressed
as means of independent data points ± SE. Data were
analyzed using a paired or unpaired Student’s t-test,
one-way ANOVA (followed by Newman-Keuls post
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